Remarkably, all 12 different cancers examined were shown to carry low levels of Atox1 and CCS gene expression (Fig. 9D), thereby suggesting their potential ability to develop resistance against cisplatin during malignancy clinical management. This evidence concerns the gene CCS and cancer.